Sorrento Therapeutics (NASDAQ: SRNE) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Sorrento Therapeutics to similar companies based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, dividends and risk.

Valuation & Earnings

This table compares Sorrento Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Sorrento Therapeutics $8.15 million -$60.92 million -3.91
Sorrento Therapeutics Competitors $290.00 million $35.57 million 150.30

Sorrento Therapeutics’ competitors have higher revenue and earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Sorrento Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics’ competitors have a beta of 0.99, indicating that their average stock price is 1% less volatile than the S&P 500.

Institutional & Insider Ownership

15.8% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.0% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sorrento Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics -15.62% -26.98% -6.39%
Sorrento Therapeutics Competitors -5,182.24% -428.32% -40.70%

Analyst Recommendations

This is a summary of current recommendations and price targets for Sorrento Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 5 0 3.00
Sorrento Therapeutics Competitors 792 3135 11397 229 2.71

Sorrento Therapeutics presently has a consensus target price of $12.60, suggesting a potential upside of 404.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.46%. Given Sorrento Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than its competitors.

Summary

Sorrento Therapeutics beats its competitors on 7 of the 12 factors compared.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.